- Home
- SMID vs GNLX Comparison
SMID vs GNLX Comparison
Compare SMID & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMID
- GNLX
- Stock Information
- Founded
- SMID 1960
- GNLX 2001
- Country
- SMID United States
- GNLX United States
- Employees
- SMID N/A
- GNLX N/A
- Industry
- SMID Building Materials
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- SMID Industrials
- GNLX Health Care
- Exchange
- SMID Nasdaq
- GNLX Nasdaq
- Market Cap
- SMID 157.4M
- GNLX 128.0M
- IPO Year
- SMID 1995
- GNLX 2023
- Fundamental
- Price
- SMID $37.10
- GNLX $3.27
- Analyst Decision
- SMID
- GNLX Strong Buy
- Analyst Count
- SMID 0
- GNLX 5
- Target Price
- SMID N/A
- GNLX $16.20
- AVG Volume (30 Days)
- SMID 10.1K
- GNLX 138.9K
- Earning Date
- SMID 07-10-2025
- GNLX 08-07-2025
- Dividend Yield
- SMID N/A
- GNLX N/A
- EPS Growth
- SMID 444.88
- GNLX N/A
- EPS
- SMID 1.86
- GNLX N/A
- Revenue
- SMID $84,450,000.00
- GNLX N/A
- Revenue This Year
- SMID N/A
- GNLX N/A
- Revenue Next Year
- SMID N/A
- GNLX N/A
- P/E Ratio
- SMID $20.45
- GNLX N/A
- Revenue Growth
- SMID 33.01
- GNLX N/A
- 52 Week Low
- SMID $25.13
- GNLX $1.83
- 52 Week High
- SMID $51.96
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- SMID 54.68
- GNLX 52.20
- Support Level
- SMID $36.06
- GNLX $3.31
- Resistance Level
- SMID $38.92
- GNLX $3.61
- Average True Range (ATR)
- SMID 1.56
- GNLX 0.23
- MACD
- SMID -0.19
- GNLX -0.03
- Stochastic Oscillator
- SMID 64.40
- GNLX 36.17
About SMID Smith-Midland Corporation
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.